跳至主要内容
临床试验/CTRI/2023/08/056757
CTRI/2023/08/056757招募中4 期

A Prospective, Observational, Multicentric, Real World Study to Evaluate Safety and Effectiveness of RAZEL (Rosuvastatin) & its combination in Clinical Practice in Indian Patients - NA

JBChemicals Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Adult (at least 18 years of age) patients of any gender who are already diagnosed with dyslipidemia and those with newly diagnosed/untreated dyslipidemia and are prescribed rosuvastatin or its combination for the treatment of dyslipidemia as a primary and secondary prevention of cardiovascular events in the Indian settings.
  • 2. Patients who are willing to provide written informed consent to share information.

排除标准

  • 1. Pregnant women and subjects/LAR who are unable or refused to provide consent will be excluded from the study. Patients having incomplete data will be excluded from the study.
  • 2. The study did not direct the treatment plans which were entirely at the discretion of the physicians.

研究者

发起方
JBChemicals Pharmaceuticals Ltd

相似试验